Back to search results

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • The Kirklin Clinic of University of Alabama Birmingham Hospital, Birmingham, Alabama, United States

    Contact: Study coordinator (Kiaron Saxton) · klsaxton@uabmc.edu · 205-767-7914

  • University of California San Diego, La Jolla, California, United States

  • Norris Comprehensive Cancer Center, Los Angeles, California, United States

    Contact: Study coordinator (Rabia Rehman) · Rabia.Rehman@med.usc.edu

  • University of California Irvine Medical Center, Orange, California, United States

    Contact: Study coordinator (Jasmin Balangue) · ucstudy@hs.uci.edu · 877-827-8839

  • University of Colorado Hospital - Anschutz Medical Campus, Aurora, Colorado, United States

    Contact: Study coordinator (Jeniffer Choi) · Jeniffer.choi@cuanschutz.edu · 303-724-9833

  • Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia, United States

  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Cheyenne Schneider) · Cheyenne.Schneider@moffitt.org · 813-745-5166

  • The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

    Contact: Study coordinator (Marina Baretti) · mbarett1@jhu.edu · 410-614-4626

  • University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

    Contact: Study coordinator (University of Michigan Rogel Cancer Center) · CancerAnswerLine@med.umich.edu · 800-865-1125

  • Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

    Contact: Study coordinator (Mohammed Najeeb Al Hallak, MD) · 800-527-6266

  • Washington University in St. Louis, St Louis, Missouri, United States

    Contact: Study coordinator (Hailey Sappington, MPH) · hailey@wustl.edu · 314-362-2582
    Contact: Study coordinator (Mina Abdiannia) · mina.a@wustl.edu · 314-273-2804

  • Memorial Sloan Kettering Cancer Center - New York, New York, New York, United States

    Contact: Study coordinator (James Harding)

  • Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States

    Contact: Study coordinator (Cancer Answer Line) · 877-585-8523

  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Susanna Ulahannan, MD) · susanna-ulahannan@ouhsc.edu · 405-271-8001

  • Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States

    Contact: Study coordinator (Carrie Manwaring) · Carrie.Manwaring@UTSouthwestern.edu · 214-645-9685

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (MD Anderson Cancer Center) · GIClinicalTrials@mdanderson.org

  • DHR Health Institute for Research and Development, McAllen, Texas, United States

    Contact: Study coordinator (Jose Cruz, DO) · jose.cruz@dhr-rgv.com
    Study coordinator · jose.cruz@dhrhealth.com

  • University of Texas Health Science Center - San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Research Department) · mccresearch@uthscsa.edu · 210-450-1000

  • Virginia Mason Medical Center, Seattle, Washington, United States

    Contact: Study coordinator (Marie Hwang) · 206-287-6280

  • Summit Cancer Centers - North Spokane, Spokane, Washington, United States

    Contact: Study coordinator (Monika Chaudhry, PhD, CCRC) · mchaudhry@summitcancercenters.com · 509-462-2273

  • Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, United States

View source on ClinicalTrials.gov(opens in a new tab)